| Literature DB >> 28178277 |
Kaitlin Rainwater-Lovett1, Carrie Ziemniak1, Douglas Watson2, Katherine Luzuriaga3, George Siberry4, Ann Petru5, YaHui Chen1, Priyanka Uprety1, Margaret McManus3, Ya-Chi Ho6, Susanna L Lamers7, Deborah Persaud1.
Abstract
The latent reservoir is a major barrier to HIV eradication. Reservoir size is emerging as an important biomarker to assess the likelihood of HIV remission in the absence of antiretroviral therapy (ART) and may be reduced by earlier initiation of ART that restricts HIV spread into CD4+ T cells. Reservoir size is traditionally measured with a quantitative viral outgrowth assay (QVOA) that induces replication-competent HIV production through in vitro stimulation of resting CD4+ T cells. However, the recent identification of replication-intact, non-induced proviral genomes (NIPG) suggests the QVOA significantly underestimates (by 62-fold) latent reservoir size in chronically-infected adults. Whether formation and persistence of Intact, NIPG is thwarted by early ART initiation and long-term virologic suppression in perinatal infection is unclear. Here, we show that the latent reservoir in 11 early treated, long-term suppressed perinatally infected children and adolescents was not inducible by QVOA and dominated by defective, NIPG. Single genome analysis of 164 NIPG from 232 million cultured resting CD4+ T cells revealed no replication-intact, near-full length sequences. Forty-three (26%) NIPG contained APOBEC3G-mediated hypermutation, 115 (70%) NIPG contained large internal deletions, one NIPG contained nonsense mutations and indels, and 5 (3%) NIPG were assigned as "Not Evaluable" due to multiple failed sequencing attempts that precluded further classification. The lack of replication competent inducible provirus and intact NIPG in this cohort indicate early, long-term ART of perinatal infection leads to marked diminution of replication-competent HIV-1 reservoirs, creating a favorable state towards interventions aimed at virologic remission.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28178277 PMCID: PMC5298215 DOI: 10.1371/journal.pone.0170548
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the study population.
| Study Participant | Age at ART Initiation (weeks) | Age at virologic suppression (months) | Current Age (years) | Duration of ART (years) | # resting CD4+ T cells analyzed (x106) | Inducible HIV by QVOA | Western Blot Interpretation | # NIPG |
|---|---|---|---|---|---|---|---|---|
| A | 6.7 | 4.5 | 13.5 | 13.4 | 30 | No | Neg | 50 |
| C | 7.1 | 3.5 | 15.3 | 15.1 | 15 | No | Neg | 3 |
| E.4 | 9.6 | 4.0 | 10.6 | 10.4 | 28 | No | 20 | |
| E.6 | 9.6 | 4.0 | 10.8 | 10.6 | 16 | No | 12 | |
| E.7 | 9.6 | 4.0 | 11.1 | 10.9 | 12 | No | +/- | 19 |
| G | 17.1 | 5.6 | 7.0 | 6.6 | 13 | No | +/- | 2 |
| I | 11.4 | 4.4 | 17.7 | 17.5 | 24 | No | Neg | 4 |
| M | 10.3 | 4.2 | 4.3 | 4.1 | 9 | No | +/- | 7 |
| N | 8.6 | 4.8 | 15.0 | 14.8 | 20 | No | Neg | 44 |
| O | 8.9 | 3.7 | 6.6 | 6.5 | 25 | No | +/- | 3 |
| D | 9.7 | 4.4 | 11.1 | 11.0 | 6 | No | +/- | 0 |
| R | 6.1 | 3.3 | 15.7 | 15.6 | 12 | No | Neg | 0 |
| S | 8.6 | 4.0 | 12.5 | 12.4 | 22 | No | +/- | 0 |
Abbreviations: QVOA, quantitative viral outgrowth assay; NIPG, non-induced proviral genome; Neg, negative; +/-, indeterminate; na, not available.
aLetter indicates participant; number indicates study visit if multiple visits.
bMedian (IQR) among the eight participants with NIPG recovered.
Fig 1Flow diagram of QVOA wells yielding NIPG.
“N” represents the number of QVOA culture wells; “n” represents the number of PCR reactions performed at limiting dilution and therefore, the number of NIPG recovered at a clonal level. QVOA: quantitative viral outgrowth assay, NIPG: non-induced proviral genomes, PCR: polymerase chain reaction.
Fig 2Classification of NIPG.
(A) Distribution of NIPG within each study participant. Purple: hypermutation; Green: Gag deletion; Red: intact near-full length, replication-deficient due to nonsense mutations or INDELs; Blue: undefined non-Gag deletion; Orange: defined non-Gag deletion; empty circle: not evaluable. (B) Distribution of NIPG across study participants after Gag and near-full length sequencing. NIPG: non-induced proviral genomes.
Fig 3Deletions in NIPG with defined junctions.
Letters and numbers correspond to participant identifiers listed in Table 1. A) Sequences are aligned to HXB2. Sequenced positions appear as a black polygon. Gray thin lines indicate deleted regions of genomes. B) Regions with relatively high coverage were extracted for phylogenetic analysis. Location shown is according to HXB2 numbering. Colors correspond to nucleotides on the left. Sequences designated with a red dot were not used in subsequent analysis due to missing sequence segments. C) Phylogenetic analysis of sequences rooted using HXB2 and aligned to positions 3350–4327 and 9105–9597.
Fig 4HIV DNA concentrations from cultured resting CD4+ T cell QVOA wells with and without NIPG.
“N” represents the number of QVOA culture wells.
HIV-specific antibody responses of plasma samples.
| Study Participant | Western Blot Interpretation | Protein-Specific Antibody Reactivity | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| gp160 | gp120 | p66 | p55 | p51 | p41 | p31 | p24 | p17 | ||
| A | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg |
| C | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg |
| E.7 | +/- | +/- | Neg | +/- | Neg | Neg | +/- | Neg | Neg | |
| G | +/- | Neg | Neg | Neg | Neg | Neg | Neg | Neg | +/- | +/- |
| I | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg |
| M | +/- | Neg | Neg | +/- | Neg | +/- | Neg | Neg | +/- | Neg |
| N | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg |
| O | +/- | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | +/- |
| D | +/- | +/- | Neg | Neg | Neg | Neg | +/- | Neg | +/- | |
| R | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg | Neg |
| S | +/- | Neg | Neg | Neg | Neg | Neg | Neg | Neg | +/- | Neg |
Abbreviations: Neg: negative; Pos: positive; +/-: indeterminate.
aLetter indicates participant; number indicates study visit if multiple visits.
bPlasma unavailable for testing from Participant E visits 4 and 6.